The Clinical Impact of the Decipher Genomic Classifier in Prostate Cancer

The Decipher genomic classifier (GC) is a 22-gene expression test that refines risk stratification and informs treatment decisions in localized prostate cancer. Traditional clinicopathologic factors, including prostate-specific antigen levels and kinetics, Gleason score, histologic variants, and tumor stage, do not fully capture disease heterogeneity, leading to potential overtreatment or undertreatment. The Decipher GC has demonstrated clinical utility across risk groups, helping to distinguish candidates for active surveillance in low-risk prostate cancer, refine the need for androgen deprivation therapy in intermediate-risk disease, and guide treatment intensification in high-risk patients. In the post-radical prostatectomy setting, the GC aids in determining the need for early salvage radiation therapy and hormonal therapy. While retrospective studies support its prognostic value, limitations include heterogeneity in study designs and the lack of established predictive utility for treatment response. Ongoing prospective trials, such as NRG GU-009 and NRG GU-010, aim to validate further the Decipher GC’s role in clinical decision-making and treatment personalization.

Cite this article as: Li S, Berg SA, Sayan M. The clinical impact of the decipher genomic classifier in prostate cancer. Eurasian J Med. 2025; 57(2), 0828, doi: 10.5152/ eurasianjmed.2025.25828.